Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Clinical trial NCT07221734 · RECRUITING
Trial details
- NCT number
- NCT07221734
- Sponsor
- mAbxience Research S.L.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-29
- Primary completion
- 2027-04-01
- Enrollment
- 632
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.